Medivation Voted Among Top Workplaces in the SF Bay Area

Medivation Voted Among Top Workplaces in the SF Bay Area 
Only Biopharmaceutical Company to Be Ranked on Bay Area News Group's
Annual List 
SAN FRANCISCO, CA -- (Marketwired) -- 06/18/13 --  Medivation, Inc.
(NASDAQ: MDVN) today announced that it was named among the top
mid-sized companies in the San Francisco Bay Area News Group's annual
Top Workplaces competition. The results of the employee survey,
published in the San Jose Mercury News were featured in the most
recent Top Workplaces special edition. Medivation earned number ten
on the list in the mid-size category and was the only
biopharmaceutical company to be ranked in this year's competition. 
"Being named a Top Workplace is a tremendous honor made possible only
by our incredible employees and I am thrilled they consider
Medivation a terrific place to work," said David Hung, M.D., founder,
president and chief executive officer of Medivation, Inc. "At
Medivation, our employees are among our greatest assets and we are
committed to providing an environment that reflects our values and
The Bay Area News Group, owner of newspapers including the Contra
Costa Times, the Oakland Tribune, and the San Jose Mercury News,
partnered with Workplace Dynamics, an independent research firm, to
conduct a survey of employees at 138 Bay Area companies. Employees
ranked their employers on company direction, execution, career path,
managers, pay and benefits. 
About Medivation
 Medivation, Inc. is a biopharmaceutical company
focused on the rapid development of novel therapies to treat serious
diseases for which there are limited treatment options. Medivation
aims to transform the treatment of these diseases and offer hope to
critically ill patients and their families. For more information,
To learn more about current career opportunities at Medivation, visit, or on LinkedIn at 
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101 
Mike Beyer (media)
Sam Brown, Inc.
(773) 463-4211 
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900 
Press spacebar to pause and continue. Press esc to stop.